CY1109264T1 - Νεες μεθοδοι για την θεραπεια και αποτροπη ειλεου - Google Patents

Νεες μεθοδοι για την θεραπεια και αποτροπη ειλεου

Info

Publication number
CY1109264T1
CY1109264T1 CY20091100828T CY091100828T CY1109264T1 CY 1109264 T1 CY1109264 T1 CY 1109264T1 CY 20091100828 T CY20091100828 T CY 20091100828T CY 091100828 T CY091100828 T CY 091100828T CY 1109264 T1 CY1109264 T1 CY 1109264T1
Authority
CY
Cyprus
Prior art keywords
methods
prevention
treatment
ileus
new methods
Prior art date
Application number
CY20091100828T
Other languages
Greek (el)
English (en)
Inventor
John J Farrar
Peter J Schied
William K Schmidt
Randall L Carpenter
Original Assignee
Adolor Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adolor Corporation filed Critical Adolor Corporation
Publication of CY1109264T1 publication Critical patent/CY1109264T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CY20091100828T 1999-11-29 2009-08-05 Νεες μεθοδοι για την θεραπεια και αποτροπη ειλεου CY1109264T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45092099A 1999-11-29 1999-11-29
EP00992255A EP1244448B1 (en) 1999-11-29 2000-11-29 Novel methods for the treatment and prevention of ileus

Publications (1)

Publication Number Publication Date
CY1109264T1 true CY1109264T1 (el) 2014-07-02

Family

ID=23790061

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100828T CY1109264T1 (el) 1999-11-29 2009-08-05 Νεες μεθοδοι για την θεραπεια και αποτροπη ειλεου

Country Status (14)

Country Link
EP (1) EP1244448B1 (cg-RX-API-DMAC7.html)
JP (2) JP5079961B2 (cg-RX-API-DMAC7.html)
AT (1) ATE432076T1 (cg-RX-API-DMAC7.html)
AU (2) AU780738B2 (cg-RX-API-DMAC7.html)
CA (1) CA2393141C (cg-RX-API-DMAC7.html)
CY (1) CY1109264T1 (cg-RX-API-DMAC7.html)
DE (1) DE60042282D1 (cg-RX-API-DMAC7.html)
DK (1) DK1244448T3 (cg-RX-API-DMAC7.html)
ES (1) ES2329004T3 (cg-RX-API-DMAC7.html)
IL (2) IL149650A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA02005336A (cg-RX-API-DMAC7.html)
NZ (1) NZ518684A (cg-RX-API-DMAC7.html)
PT (1) PT1244448E (cg-RX-API-DMAC7.html)
WO (1) WO2001042207A2 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274591B1 (en) 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
PL2368554T3 (pl) 2003-04-08 2015-05-29 Progenics Pharm Inc Preparaty farmaceutyczne zawierające metylonaltrekson
US6992090B2 (en) * 2003-06-16 2006-01-31 Adolor Corporation Substituted piperidine compounds and methods of their use
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
MX2007010833A (es) 2005-03-07 2009-02-17 Univ Chicago Uso de antagonistas opioides para atenuar proliferacion y migracion de células endoteliales.
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
CN101426481B (zh) 2006-04-21 2012-12-05 帝斯曼知识产权资产管理有限公司 阿片受体拮抗剂的用途
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
JP5469593B2 (ja) 2007-03-29 2014-04-16 ワイス・エルエルシー 末梢性オピオイド受容体アンタゴニストおよびその使用
MX2009010550A (es) 2007-03-29 2009-12-14 Progenics Pharm Inc Formas de cristal de bromuro de (r)-n-metilnaltrexona y uso de las mismas.
WO2008121348A2 (en) 2007-03-29 2008-10-09 Progenics Pharmaceuticals, Inc. Peripheral opioid receptor antagonists and uses thereof
AU2008349873B2 (en) 2008-02-06 2014-02-13 Progenics Pharmaceuticals, Inc. Preparation and use of (R),(R)-2,2'-bis-methylnaltrexone
CA2719134C (en) 2008-03-21 2015-06-30 The University Of Chicago Treatment with opioid antagonists and mtor inhibitors
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
RU2455943C1 (ru) * 2011-02-01 2012-07-20 Государственное образовательное учреждение высшего профессионального образования "Российский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" (ГОУ ВПО РГМУ Росздрава) Способ лечения обтурационной формы острой спаечной тонкокишечной непроходимости

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1420015B1 (de) * 1959-10-16 1971-08-26 Boehringer Sohn Ingelheim 2'-Hydroxy-5,9-dimethyl-6,7-benzomorphane
US4176186A (en) * 1978-07-28 1979-11-27 Boehringer Ingelheim Gmbh Quaternary derivatives of noroxymorphone which relieve intestinal immobility
FR2514644A1 (fr) * 1981-10-19 1983-04-22 Sanofi Sa Composition pharmaceutique a action antagoniste peripherique des opiaces
WO1983003197A1 (en) * 1982-03-16 1983-09-29 Univ Rockefeller Method for controlling gastrointestinal dysmotility
US4806556A (en) * 1985-12-12 1989-02-21 Regents Of The University Of Minnesota Gut-selective opiates
US4730048A (en) * 1985-12-12 1988-03-08 Regents Of The University Of Minnesota Gut-selective opiates
US5250542A (en) * 1991-03-29 1993-10-05 Eli Lilly And Company Peripherally selective piperidine carboxylate opioid antagonists
US6274591B1 (en) * 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds

Also Published As

Publication number Publication date
NZ518684A (en) 2003-11-28
PT1244448E (pt) 2009-06-30
WO2001042207A3 (en) 2002-05-02
DK1244448T3 (da) 2009-08-17
DE60042282D1 (de) 2009-07-09
ES2329004T3 (es) 2009-11-20
JP2012162560A (ja) 2012-08-30
CA2393141A1 (en) 2001-06-14
EP1244448A2 (en) 2002-10-02
MXPA02005336A (es) 2003-01-28
AU2005203041B2 (en) 2009-01-08
EP1244448B1 (en) 2009-05-27
EP1244448A4 (en) 2003-06-25
ATE432076T1 (de) 2009-06-15
IL149650A (en) 2011-02-28
WO2001042207A2 (en) 2001-06-14
JP5079961B2 (ja) 2012-11-21
AU2005203041A1 (en) 2005-08-04
JP5460771B2 (ja) 2014-04-02
IL149650A0 (en) 2002-11-10
CA2393141C (en) 2013-08-13
AU780738B2 (en) 2005-04-14
JP2003517476A (ja) 2003-05-27
AU3970501A (en) 2001-06-18

Similar Documents

Publication Publication Date Title
IL149650A0 (en) Novel methods for the treatment and prevention of ileus
DE60234183D1 (de) Verwendung von methylnaltrexon zur behandlung von immunsuppression
WO2001041705A3 (en) Novel methods for the treatment and prevention of dizziness and pruritus
DE69841663D1 (de) Verwendung von methylnaltrexon und verwandten verbindungen
WO2003070191A3 (en) Tamper-resistant transdermal opioid delivery devices
CA2548834A1 (en) Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same
HK1055078A1 (zh) 使用纳布啡和鸦片拮抗剂治疗疼痛的方法
NZ331001A (en) Use of an opiate K receptor agonist as an antipruritic
IL134796A0 (en) Noribogaine in the treatment of pain and drug addiction
IL149378A0 (en) Composition for treatment of constipation and irritable bowel syndrome
WO2004096122A3 (en) Use of ngf antagonists and opioids for treating pain
MXPA05010819A (es) Uso de antagonistas de opioide perifericos, especialmente metilnaltrexona para tratar sindrome de intestino irritable.
BR0207316A (pt) Derivados de epotilona para o tratamento de tumores refratários
EP0915094A4 (en) MORPHINANE DERIVATIVES AND MEDICAL USE THEREOF
BR0207978A (pt) N-but-3enil norbuprenorfina e métodos de uso
ATE465735T1 (de) Verwendung einer kombination von morphin und mindestens einem opiatantagonisten zur behandlung von opiatabhängigkeit und zur verhinderung des nicht-oralen opiatmissbrauchs bei opiatsüchtigen
IL120495A0 (en) Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer
EP1095655A3 (en) NK-1 receptor antagonists and eletriptan for the treatment of migraine
HK1080004A (en) Methods for treating pain by administering a nerve growth factor antagonist and an opioid analgesic and compositions containing the same